Skip to content

Atea Pharmaceuticals, Inc.

AVIR

CIK 0001593899

← back to feed
Revenue (TTM)
$351.37M
+622.5% YoY Q1 May 2026
Net Income (TTM)
−$158.92M
+6.0% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.94
+3.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-49.5%
Q1 May 2026
Net Margin
-45.2%
Q1 May 2026
Free Cash Flow (TTM)
−$148.61M
Q1 May 2026
Cash
$79.32M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
80.03M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings